Skip to content
ESPT
MARKETS / NASDAQ / Health care / Pharmaceuticals / AMPH
NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Amphastar Pharmaceuticals, Inc. AMPH

14 fiscal years on record · USD · FY2025 reported · SEC filings only
$719.9M
▼ 1.7% YoY
$98.1M
▼ 38.5% YoY
$121.2M
▼ 29.7% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

It currently manufactures and sells over 25 prescription pharmaceutical products, along with an over-the-counter product, Primatene MIST. As of December 31, 2025, it had 1,976 full-time employees in the United States, China, and France. Its manufacturing facilities are located in Rancho Cucamonga and South El Monte, California; Canton, Massachusetts; Éragny-sur-Epte, France; and Nanjing, China. As of December 31, 2025, it owned or leased a total of 69 buildings at six locations in the United States, France and China, comprising 2.5 million square feet of manufacturing, research and development, distribution, packaging, laboratory, office and warehouse space. For the year ended December 31, 2025, McKesson accounted for 24% of its net revenues. It was incorporated in California under the name Amphastar Pharmaceuticals, Inc. in 1996 and merged into a newly formed Delaware corporation of the same name in 2004.

Written from the business description in Amphastar Pharmaceuticals, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth

USD 719.9M
Revenue, FY2025 · full 14-year series below
Revenue $M Net income $M
FY2025 · Revenue 719.9 · Net income 98.1
300M600M
201220152018202120242025
Compound annual growth
+13.0%
+15.5%
+11.1%
+2.4%
+133.8%
+5.3%
+132.3%
+49.5%
+299.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +15.5% a year over the five years to FY2025 — but profit grew faster: net income at +133.8%, earnings per share at +132.3%.

The share count fell from 0.05B to 0.05B — the buyback concentrates the same profit into fewer slices.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

14 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 19.5% · Net 13.6%
10%20%30%-5%
201220182025
ROE
FY2025 · ROE 12.9%
10%20%-2%-4%
201220182025
Three returns, three denominators.
Gross margin49.5%
Operating margin19.5%
Net margin13.6%
EBITDAUSD 172.1M

Each USD of equity produced 13 cents of profit this year.

Cash & shareholders

USD 69.2M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 121.2
100M200M-10M-20M
201220182025
Net buybacks $M Dividends $M
FY2025 · Dividends · · Net buybacks 69.2
30M60M-5M-10M
20122014201620182020202220242025
Dividends paid·
Net buybacksUSD 69.2M
Share of profit70.5%
Consecutive raises·

USD 69.2M in buybacks — 71% of the year's profit went back to shareholders.

Total assetsUSD 1.6B
CashUSD 170.2M
Gross debtUSD 619.7M
Net debtUSD 449.5M
Current ratio4.02×

Net debt stands at 57% of equity.

The 14-year record

14 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
AMPH, 14-year financial record
Metric 20252024202320222021202020192018201720162015201420132012
Revenue $B0.70.70.60.50.40.30.30.30.20.30.30.20.20.2
Operating income $B0.10.20.20.10.10.0−0.0−0.0−0.00.0−0.0−0.00.00.0
EBITDA $B0.20.20.20.10.10.00.0−0.00.00.00.0−0.00.00.0
Income tax $B0.00.00.00.00.00.00.0−0.0−0.00.0−0.0−0.00.00.0
Net income $B0.10.20.10.10.10.00.0−0.00.00.0−0.0−0.00.00.0
Free cash flow $B0.10.20.10.10.10.00.0−0.00.00.0−0.00.00.0−0.0
EPS, diluted $2.033.062.601.741.250.030.98−0.120.080.21−0.06−0.250.310.46
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend——————————————
ROE %12.923.323.618.814.70.413.7−1.71.13.1−1.0−4.04.97.8
Shares out B0.050.050.050.050.050.050.050.050.050.050.050.040.04◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · LLY
Provenance

Company facts, as filed

How we verify · 0 failures in 68 reconciliationsAUDITED

Reconciled in 14 of the 14 fiscal years we could check. 12 checks were skipped: the balance sheet is not tagged before 2013. Five checks were skipped: EPS is not tagged before 2012. Five checks were skipped: revenue is not tagged before 2012.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsDecember 31
Data on record since2012

Share this section

Download image